Weekly Low-Dose Doxorubicin as Second Line Therapy in Advanced Breast Cancer

Authors

  • I. Elomaa From the Department of Radiotherapy and Oncology, University of Helsinki, SF-00290, Helsinki, Finland
  • C. Blomqvist From the Department of Radiotherapy and Oncology, University of Helsinki, SF-00290, Helsinki, Finland
  • P. Rissanen From the Department of Radiotherapy and Oncology, University of Helsinki, SF-00290, Helsinki, Finland

DOI:

https://doi.org/10.3109/02841868809094360

Keywords:

Chemotherapy, advanced breast cancer, low-dose doxorubicin

Abstract

Abstract

This is a retrospective analysis of women whose advanced breast cancer was treated with weekly low-dose doxorubicin (12 mg/m2) as second line therapy. The patients received doxorubicin as single agent therapy (group D, n=47) or combined with various cytotoxic (group D+CT, n=52) or with hormonal drugs (group D+ET, n=37). Objective responses were found in 23% in group D, in 33% in group D+CT and in 30% in group D+ET. Mean response duration was 11 months in group D+CT and group D+ET and 6 months in group D (p=0.007, Student's t-test). Median survival was 17 months in group D+CT and 9 months both in group D and group D+ET (p=0.01, Mantel-Cox). The toxicity was mild. However, nausea occurred more often in group D+CT than in group D (p=0.009, chi-square-test).

Downloads

Download data is not yet available.

Downloads

Published

1988-01-01

How to Cite

Elomaa, I., Blomqvist, C., & Rissanen, P. (1988). Weekly Low-Dose Doxorubicin as Second Line Therapy in Advanced Breast Cancer. Acta Oncologica, 27(6), 799–801. https://doi.org/10.3109/02841868809094360

Issue

Vol. 27 No. 6 (1988): Acta Oncologica

Section

Articles